Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Thursday, December 3, 2009, 5:00AM ET - U.S. Markets open in 4 hours and 30 minutes. Dow Down 0.18% Nasdaq  0.00%
VIVUS Inc. (VVUS)On Dec 2: 8.50   0.00 (0.00%)  
MORE ON VVUS
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
VIVUS Inc.
1172 Castro Street
Mountain View, CA 94040
United States - Map
Phone: 650-934-5200
Fax: 650-934-5379
Web Site: http://www.vivus.com

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:130

BUSINESS SUMMARY 
VIVUS, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for underserved markets in the United States. The company offers MUSE, a minimally invasive therapy for erectile dysfunction. It develops drug candidates that address the need of obesity, diabetes, and sexual health markets. The company’s late-stage clinical products, which are under development, include Qnexa that is in phase 3 clinical trials for obesity and completed phase 2 clinical trials for diabetes; Avanafil, which is in phase 3 studies to treat erectile dysfunction; and Luramist, for which the phase 2 study is completed for the treatment of hypoactive sexual desire disorder in women. It has a development, licensing, and supply agreement with Tanabe Seiyaku Co., Ltd. for the development of Avanafil; and licensing agreements with Acrux and its subsidiary to develop and, if approved, commercialize Luramist and Evamist in the United States. The company was founded in 1991 and is headquartered in Mountain View, California.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on VIVUS Inc.


    CORPORATE GOVERNANCE 
    VIVUS Inc.'s Corporate Governance Quotient (CGQ®) as of 1-Dec-09 is better than 40.5% of Russell 3000 companies and 45.1% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Mr. Leland F. Wilson , 64
    Chief Exec. Officer
    $ 734.00K $ 375.00K
    Mr. Peter Y. Tam , 45
    Pres
    $ 396.00K $ 68.00K
    Dr. Virgil A. Place M.D., 84
    Founder, Chief Scientific Officer
    N/A N/A
    Mr. Tim Morris CPA, 47
    Chief Financial Officer and VP of Fin.
    N/A N/A
    Mr. Guy P. Marsh , 55
    VP of U S Operations and Gen. Mang.
    $ 353.00K $ 837.00K
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis